Strategic Performance Drivers
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
-
Revenue growth of 127% was primarily driven by a significant increase in surgical procedure volumes and the integration of the SImmetry+ system acquired last year.
-
Gross margin expanded by approximately 21 percentage points to 64%, attributed to improved absorption of fixed production overhead and a more streamlined commercial footprint.
-
Management identifies physician and distributor training as a leading indicator for growth, noting a 98% increase in training events during the first half of 2026.
-
The commercial strategy focuses on positioning Catamaran and SImmetry+ as complementary tools for inferior, posterior, and lateral approaches to the same anatomy.
-
Operational efficiency improved through the reclassification of certain Catamaran instruments from disposable to reusable status following a recent FDA 510(k) clearance.
-
The new Tampa sales and training office has exceeded expectations, contributing to a record case value month in July and a strong start to the third quarter.
Outlook and Strategic Initiatives
-
Management expects gross margin expansion to continue as revenue increases and fixed costs are further absorbed within the cost of sales.
-
The company plans to add further sales heads and distributor partners in the second half of the year to support commercial expansion.
-
An enhanced SImmetry+ system featuring streamlined decortication is scheduled to become clinically active in the third quarter of 2026.
-
Tenon is nearing an FDA 510(k) filing for a novel posterior approach technology, which is currently finishing testing phases.
-
A diversified portfolio of sacropelvic technologies is expected to be delivered over the next 6 to 9 months through multiple R&D launches.
Financial and Regulatory Developments
-
A public offering closed on July 1, 2026, generating $4.2 million in gross proceeds to fund commercial expansion, clinical research, and debt repayment.
-
Net loss for the first six months of the year included $900 thousand of non-cash interest expense. related to the amortization of original issue discounts on convertible notes.
-
FDA 510(k) clearance received on July 2 for the Catamaran system includes instrument upgrades expected to reduce per-procedure costs starting in Q3.
-
Operating expenses increased to $4.2 million, primarily due to higher sales and marketing costs associated with revenue growth and increased R&D investment.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
Q&A Session Summary
Advancements and regulatory status of the SiVantage product pipeline
-
Management confirmed the SImmetry+ platform will see significant enhancements over the next 2 to 6 months, including a new decortication tool in October.
-
Testing is being finalized for a novel posterior approach technology, with an FDA submission expected in the near future.
-
The SiVantage portfolio is performing as expected, providing a foundation for lateral oblique procedure growth.
Seasonality of physician training and impact of the Tampa facility
-
Despite typical summer seasonality, the company is seeing an uptick in training demand due to the immersive environment of the new Tampa facility.
-
The facility allows physicians to evaluate the full array of technologies, including imaging and navigation, which has driven record training activity.
-
Management anticipates continued momentum as new product enhancements provide additional reasons for physicians to visit the site.
